NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

NewAmsterdam Pharma (NASDAQ:NAMS) had its price objective boosted by research analysts at Stifel Nicolaus from $44.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 48.46% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Citigroup increased their price objective on NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Wells Fargo & Company assumed coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They set an “overweight” rating and a $45.00 price target for the company. HC Wainwright initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada lifted their target price on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.90.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $33.68 on Tuesday. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $42.00. The stock has a market cap of $3.82 billion, a P/E ratio of -16.43 and a beta of 0.05. The firm has a fifty day moving average price of $37.29 and a 200 day moving average price of $28.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $4.54 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

A number of institutional investors have recently added to or reduced their stakes in NAMS. Deutsche Bank AG grew its position in NewAmsterdam Pharma by 2,634.0% during the first quarter. Deutsche Bank AG now owns 72,397 shares of the company’s stock worth $1,482,000 after buying an additional 69,749 shares during the period. Aberdeen Group plc boosted its stake in shares of NewAmsterdam Pharma by 110.5% during the 1st quarter. Aberdeen Group plc now owns 376,863 shares of the company’s stock worth $7,714,000 after acquiring an additional 197,803 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of NewAmsterdam Pharma by 52.6% in the 1st quarter. American Century Companies Inc. now owns 528,830 shares of the company’s stock worth $10,825,000 after acquiring an additional 182,258 shares during the period. Wellington Management Group LLP increased its stake in NewAmsterdam Pharma by 53.0% in the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock valued at $72,504,000 after purchasing an additional 1,226,852 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp increased its stake in NewAmsterdam Pharma by 83.9% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 37,700 shares of the company’s stock valued at $772,000 after purchasing an additional 17,200 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.